TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 8, 2012, Pages 1042-1047

  Offersen, Rasmus ^a   Melchjorsen, Jesper ^a   Paludan, Søren R ^b   Østergaard, Lars ^a   Tolstrup, Martin ^a   Søgaard, Ole S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Adjuvants; Cellular memory; CpG ODN; HIV; Pneumococcal vaccine; TLR9

Indexed keywords

AGATOLIMOD; BACTERIAL POLYSACCHARIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN BETA; PLACEBO; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MALE; MOLECULAR DYNAMICS; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, BACTERIAL; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PLACEBOS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84866129742     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20707     Document Type: Article

References (19)

1. López-Palomo C, Martín-Zamorano M, Benítez E, Fernández-Gutiérrez C, Guerrero F, Rodríguez-Iglesias M, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517-24; PMID:14981752; http://dx.doi.org/10.1002/jmv.20045.
2. Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345-53; PMID:18834317; http://dx.doi.org/10.1086/592692.
3. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23:407-13; PMID:21514128; http://dx.doi.org/10.1016/j.coi.2011.04. 002.
4. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006; 311:155-78; PMID:17048708; http://dx.doi.org/10.1007/3-540-32636-7-6.
5. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; PMID:16763660; http://dx.doi.org/10.1038/ nrd2059.
6. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42-50; PMID:20504165; http://dx.doi.org/10.1086/653112.
7. Bacterial Respiratory Pathogen Reference Laboratory. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG. Available at: http://www.vaccine.uab.edu/ ELISA%20Protocol.pdf. Accessed 13 April 2010.
8. Lucas AH, Apicella MA, Taylor CE. Carbohydrate moieties as vaccine candidates. Clin Infect Dis 2005; 41:705-12; PMID:16080094; http://dx.doi.org/ 10.1086/432582.
9. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with proteinpolysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20; PMID:19214194; http://dx.doi.org/10.1038/nri2494.
10. Lai Z, Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine 2009; 27:3137-44; PMID:19446183; http://dx.doi.org/10.1016/j.vaccine.2009.03.064.
11. Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011; 17:1602-9; PMID:22101769; http://dx.doi.org/10.1038/nm. 2535.
12. Sahly H, Keisari Y, Crouch E, Sharon N, Ofek I. Recognition of bacterial surface polysaccharides by lectins of the innate immune system and its contribution to defense against infection: the case of pulmonary pathogens. Infect Immun 2008; 76:1322-32; PMID:18086817; http://dx.doi.org/10.1128/IAI. 00910-07.
13. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek TB. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007; 26:605-16; PMID:17462920; http://dx.doi.org/10.1016/j.immuni.2007.03.012.
14. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 2009; 21:185-93; PMID:19502082; http://dx.doi.org/10.1016/j.smim.2009.05.005.
15. Sen G, Khan AQ, Chen Q, Snapper CM. In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol 2005; 175:3084-91; PMID:16116197.
16. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 2006; 80:267-77; PMID:16731773; http://dx.doi.org/10.1189/jlb.1105626.
17. Heidelberger M, Horton D, Haskell TH. Cross-reactions of lipopolysaccharides of Pseudomonas aeruginosa in antipneumococcal and other antisera. Infect Immun 1986; 54:928-30; PMID:3096896.
18. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharmacol 2006; 6:1267-76; PMID:16782539; http://dx.doi.org/10.1016/j. intimp.2006.03.009.
19. Aebig JA, Mullen GE, Dobrescu G, Rausch K, Lambert L, Ajose-Popoola O, et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007; 323:139-46.